Six weeks after Rwanda-backed rebels captured the eastern Congolese cities of Goma and Bukavu, the region is facing a setback ...

NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.

Severe mpox and long-term sequelae such as severe scarring were more likely to occur among HIV-positive patients with detectable viral loads and low CD4 counts.

The Eastern Democratic Republic of the Congo is suffering a severe setback in its fight against the Mpox outbreak, six weeks after rebels supported by Rwanda took control of two major cities. The DRC ...

AP Hospitals across eastern Congo that were once at the forefront of the country’s response to the mpox outbreak are facing a setback in detecting the disease and offering treatment following the ...

A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.

The results from STOMP reinforce the value of randomized clinical trials during outbreaks of infectious diseases, like mpox,” said Past ACTG Chair Judith Currier M.D., M.Sc. “There was considerable ...

Nurses are administering medicine to Mpox patients at a tent in Kabare, Democratic Republic of the Congo, as the area ...

Tanzania has confirmed its first two cases of mpox, the health ministry said Monday, the first time the virus has been ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...